Baxter International Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Myxredlin
Myxredlin (pronounced mix-RED-lin) is the first and only ready-to-use insulin for IV infusion in the hospital and other acute care settings.
The insulin for IV infusion features an extended shelf life of 30 days at room temperature (77 degrees F) or 24 months if refrigerated (36 degrees F to 46 degrees F in the original carton to protect from light.
Myxredlin is provided in a standardized concentration of 100 units/100 mL in a flexible plastic container.
This innovative presentation helps ensure Myxredlin delivers a consistent, stable and predictable concentration with every administration, which is a key consideration for patient safety.
“Insulin is in the top five drug classes involved with medication errors, and more than 30 percent of those errors result in patient harm,” said Robert Felicelli, president, Pharmaceuticals, Baxter. “With the launch of Myxredlin, clinicians will have access to a convenient, reliable presentation of ready-to-use insulin that can help ensure a faster delivery to patients, streamlined workflow for pharmacists and nurses, and less waste for hospitals.”
Myxredlin is indicated for use as short-acting human insulin to improve glycemic control in adults and pediatric patients with diabetes mellitus.
Myxredlin is intended for use only in acute care settings under medical supervision.
Myxredlin is expected to be available from Baxter in the United States before the end of the year.
- Baxter International Inc. (2019, July 22). Baxter Announces U.S. FDA Approval of Myxredlin, The First and Only Ready-To-Use Insulin for IV Infusion. Business Wire. Retrieved July 22, 2019, from https://www.businesswire.com/news/home/20190722005371/en